Pembrolizumab as adjuvant therapy in non-small-cell lung cancer. Sorscher S. Lancet Oncol 2022;23:e529.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sorscher S. Pembrolizumab as adjuvant therapy in non-small-cell lung cancer. Lancet Oncol 2022;23:e529.
PMID: 36455578